Analytical Data
-
Gene name
DPAGT1
- Application
-
Alternative Names
DPAGT1；DPAGT2；UDP-N-acetylglucosamine--dolichyl-phosphate N-acetylglucosaminephosphotransferase
-
Species
Human
-
Source
E. coli
-
Tag
His tag N-Terminus
-
Purity
Greater than 90% as determined by SDS-PAGE.
-
Uniprot
Q9H3H5
-
Expression Region
1-408aa
-
AA Sequence
MWAFSELPMPLLINLIVSLLGFVATVTLIPAFRGHFIAARLCGQDLNKTSRQQIPESQGVISGAVFLIILFCFIPFPFLNCFVKEQCKAFPHHEFVALIGALLAICCMIFLGFADDVLNLRWRHKLLLPTAASLPLLMVYFTNFGNTTIVVPKPFRPILGLHLDLGILYYVYMGLLAVFCTNAINILAGINGLEAGQSLVISASIIVFNLVELEGDCRDDHVFSLYFMIPFFFTTLGLLYHNWYPSRVFVGDTFCYFAGMTFAVVGILGHFSKTMLLFFMPQVFNFLYSLPQLLHIIPCPRHRIPRLNIKTGKLEMSYSKFKTKSLSFLGTFILKVAESLQLVTVHQSETEDGEFTECNNMTLINLLLKVLGPIHERNLTLLLLLLQILGSAITFSIRYQLVRLFYDV
-
Molecular Weight
46 kDa
-
Endotoxin
< 1.0 EU per μg protein as determined by the LAL method.
-
Form
Freeze-dried powder
-
Buffer formulation
PBS, pH7.4, containing 0.01% SKL, 1mM DTT, 5% Trehalose and Proclin300.
-
Reconstitution
Reconstitute in ddH2O to a concentration of 0.1-0.5 mg/mL. Do not vortex.
- Customization
-
Stability Test
The thermal stability is described by the loss rate. The loss rate was determined by accelerated thermal degradation test, that is, incubate the protein at 37℃ for 48h, and no obvious degradation and precipitation were observed. The loss rate isless than 8% within the expiration date under appropriate storage condition.
-
Storage & Shelf Life
Samples are stable for up to twelve months from date of receipt at -20℃ to -80℃. Store it under sterile conditions at -20℃ to -80℃. It is recommended that the protein be aliquoted for optimal storage. Avoid repeated freeze-thaw cycles.
-
Shipping
In general, recombinant proteins are supplied as lyophilized powder and shipped at ambient temperature. For bulk packages, the proteins are provided as frozen liquid and shipped with blue ice, unless otherwise requested by the customer.
Quality inspection process
Related Products
Protein Description
DPAGT1 (Dolichyl-Phosphate N-Acetylglucosamine Phosphotransferase 1) is a crucial enzyme involved in the initial steps of N-glycosylation, a vital post-translational modification that influences protein folding, stability, and cell signaling. Mutations in the DPAGT1 gene can lead to a rare genetic disorder known as congenital disorder of glycosylation type IIb (CDG-IIb), characterized by neurodevelopmental defects, impaired glycoprotein synthesis, and various clinical manifestations. Given the significance of DPAGT1 in maintaining cellular homeostasis and the pathological consequences of its dysfunction, the study of recombinant DPAGT1 protein has garnered attention to elucidate its structure, function, and the molecular mechanisms underlying its enzymatic activity. Research involving recombinant DPAGT1 aims to enhance our understanding of its role in glycoprotein biosynthesis and offers potential therapeutic avenues for treating associated disorders. By expressing DPAGT1 in heterologous systems, scientists can investigate the enzyme's catalytic properties, identify substrates, and assess how mutations impact its function. This knowledge is essential for developing targeted treatments or biotherapeutics for patients with CDG-IIb, paving the way for innovative intervention strategies and improving patient outcomes.
